Simulations Plus (SLP) Q1 2026: Services Backlog Jumps 18% as Biotech Spend Rebounds

2026-01-08 | By EarningsIQ Research

Services momentum and a rising backlog signal a turning point in client spending for Simulations Plus, as the biotech funding environment improves and regulatory support for in silico methods grows. Despite a dip in software revenue, management maintains full-year guidance, banking on seasonality and a robust client pipeline to drive a second-half software rebound. Platform integration, AI-driven tools, and a focus on regulatory-grade modeling remain central to SLP’s long-term strategy, with near-term execution hinging on software renewal rates and continued services strength.

Summary

• Services Backlog Expansion: Growing project pipeline and client budget flush drive optimism for 2026.
• Software Lags, Guidance Holds: Management expects seasonality and renewals to restore software mix in coming quarters.
• AI and Ecosystem Integration: Strategic focus on cloud, AI, and regulatory-compliant workflows underpins future growth.

Performance Analysis

Simulations Plus reported a 3% revenue decline in Q1 2026, as expected, with software revenue down 17% and services revenue up 16% year over year. The shift in revenue mix was notable: services comprised 52% of total revenue, overtaking software at 48%, a reversal from historical norms. Development products (GastroPlus, Monolix Suite) remained the largest software contributors, while clinical operations software (Proficiency) saw a sharp year-over-year drop, reflecting tough comps and ongoing clinical trial startup headwinds.

Services strength was broad-based, with development services up 8% and commercialization services (MedCom, medical communications services) surging 42% for the quarter. Backlog grew 18% to $20.4 million, indicating increased client project activity and a possible leading indicator for future software demand. Gross margin improved to 59%, with both software and services margins recovering on the back of prior year cost actions and improved utilization.

• Backlog Acceleration: Services backlog up 18% year over year, reflecting improved client budget confidence.
• Software Renewal Pressure: Renewal rates at 88%, below historical norms, as client consolidation and delayed signings impact flow.
• Margin Recovery: Gross margin expansion driven by cost discipline and higher services efficiency post-reorganization.

Cash remains solid at $35.7 million with no debt, supporting continued investment in product development and strategic initiatives. While the quarter’s headline results were mixed, underlying services momentum and backlog growth provide a constructive setup for the rest of the year.

Executive Commentary

Strategic Positioning

1. Integrated Product Ecosystem

SLP is executing on a multi-year vision to unify its modeling, simulation, and analytics platforms—including GastroPlus, Monolix Suite, AdMet Predictor, and QSP (quantitative systems pharmacology) modules—into a seamless, cloud-enabled ecosystem. This approach aims to provide end-to-end workflows from discovery through commercialization, with interoperability and regulatory-grade science as differentiators.

2. AI and Regulatory Alignment

Artificial intelligence is being embedded into core products (notably GastroPlus), driving both client interest and pricing power. Management highlighted recent FDA support for in silico (computer-based) methodologies as a tailwind, positioning SLP to benefit as regulatory acceptance grows and clients seek validated, compliant AI solutions.

3. Services as a Leading Indicator

Services activity is seen as a bellwether for software demand, with increased client spending on consulting and project work typically preceding expansions in software licensing. The recent surge in services bookings and backlog is viewed as an early sign of broader budget recovery in biotech and pharma R&D.

4. Capital Allocation and Cost Discipline

Recent organizational restructuring and a reduction in force have improved services margins and freed up resources for R&D investment. SLP remains debt-free, with a focus on maintaining operating expenses at 50% of revenue and channeling 15-17% of revenue into R&D, supporting accelerated product innovation.

Key Considerations

This quarter’s results highlight a business in transition, balancing near-term software softness against longer-term ecosystem and AI-driven opportunities.

Key Considerations:

• Backlog as a Growth Signal: The 18% increase in services backlog suggests clients are unlocking budgets, which could drive software demand in subsequent quarters.
• Software Mix Seasonality: Software’s share of revenue is expected to rebound in Q2 and Q3, as renewal cycles and client expansion plans play out.
• AI Monetization Potential: Early client feedback on AI features is positive, with SLP already embedding price increases and planning further monetization through modular offerings.
• Renewal Rate Watch: An 88% renewal rate, while stable, remains below historical 90%+ levels, requiring close monitoring as client consolidation and delayed signings remain headwinds.

Risks

Key risks include continued volatility in biotech funding, which could stall the recovery in client budgets, and potential for lumpy software revenue, especially in QSP perpetual licenses. Renewal rates below historical norms and ongoing client consolidation could further pressure software growth if not offset by new client wins or upsells. Regulatory shifts, while currently favorable, remain an external variable.

Forward Outlook

For Q2 2026, Simulations Plus guided to:

• Revenue of approximately $21 to $22 million.

For full-year 2026, management maintained guidance:

• Total revenue of $79 to $82 million (0% to 4% YoY growth).
• Software mix of 57% to 62%.
• Adjusted EBITDA margin of 26% to 30%.
• Adjusted diluted EPS of $1.03 to $1.10.

Management emphasized several factors shaping the outlook:

• Seasonal software renewal patterns expected to drive a mix shift in coming quarters.
• Robust services backlog and pipeline provide visibility into near-term revenue and project flow.

Takeaways

SLP enters 2026 with improved services momentum and a growing backlog, setting the stage for a potential software rebound as client budgets stabilize. AI and ecosystem integration remain central to the long-term value proposition, while near-term execution will hinge on renewal rates and conversion of backlog into software upsell.

• Backlog and Pipeline Strength: The 18% backlog increase is a clear signal of improving client engagement and spend, especially in services.
• Software Recovery Hinges on Renewals: With renewal rates below historical levels and tough QSP comps, the next two quarters are critical for software growth to match guidance.
• AI Adoption and Pricing: Early traction with AI features supports pricing power and future modular revenue streams, but monetization is still ramping.

Conclusion

Simulations Plus delivered a mixed but strategically promising quarter, with services momentum and backlog expansion offsetting software headwinds. Execution on renewal rates and software upsell will be decisive, but the company’s integrated, AI-enabled platform and strong balance sheet provide multiple levers for value creation in 2026 and beyond.

Industry Read-Through

SLP’s results confirm a thaw in biotech and pharma R&D budgets, with services providers seeing early benefit as clients unlock project spend. Regulatory support for in silico modeling and AI-enabled workflows is accelerating, suggesting that software and analytics vendors with validated, compliant solutions are best positioned for the next phase of industry growth. Backlog growth and margin recovery at SLP may serve as a leading indicator for peers in biosimulation, CRO (contract research organization), and scientific software, especially as the sector shifts toward integrated, cloud-first platforms.

SLP Healthcare Scientific Software AI Biosimulation Services Backlog Drug Development